BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32662896)

  • 1. Induction of antibody responses in mice immunized intranasally with Type I interferon as adjuvant and synergistic effect of chitosan.
    Maeyama JI; Kurata-Iesato Y; Isaka M; Komiya T; Sakurai S
    Microbiol Immunol; 2020 Sep; 64(9):610-619. PubMed ID: 32662896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid.
    Maeyama J; Komiya T; Takahashi M; Isaka M; Goto N; Yamamoto S
    Vaccine; 2009 Feb; 27(8):1166-73. PubMed ID: 19136040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
    Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
    Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.
    Mills KH; Cosgrove C; McNeela EA; Sexton A; Giemza R; Jabbal-Gill I; Church A; Lin W; Illum L; Podda A; Rappuoli R; Pizza M; Griffin GE; Lewis DJ
    Infect Immun; 2003 Feb; 71(2):726-32. PubMed ID: 12540551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
    Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
    Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
    PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
    Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.
    Singh J; Pandit S; Bramwell VW; Alpar HO
    Methods; 2006 Feb; 38(2):96-105. PubMed ID: 16442811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
    Pirouzmand H; Khameneh B; Tafaghodi M
    Pharm Biol; 2017 Dec; 55(1):212-217. PubMed ID: 27927058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH; Dai WJ; Chen B; Fan XY
    Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
    Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
    McNeela EA; Jabbal-Gill I; Illum L; Pizza M; Rappuoli R; Podda A; Lewis DJ; Mills KH
    Vaccine; 2004 Feb; 22(8):909-14. PubMed ID: 15161067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant.
    Mariotti S; Teloni R; von Hunolstein C; Romagnoli G; Orefici G; Nisini R
    Vaccine; 2002 May; 20(17-18):2229-39. PubMed ID: 12009277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.